XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.0.1
SEGMENTS (Tables)
9 Months Ended
Dec. 31, 2023
SEGMENTS  
Summary of results of segments

Three Months Ended December 31,

Nine Months Ended December 31,

(Dollars in millions)

    

2023

    

2022

    

2023

    

2022

Revenue

United States

$

1,032

$

1,265

$

3,305

$

3,581

Japan

581

606

1,761

1,855

Principal Markets

1,446

1,472

4,395

4,460

Strategic Markets

877

961

2,741

2,874

Total revenue

$

3,936

$

4,303

$

12,202

$

12,771

Segment adjusted EBITDA

United States

$

194

$

271

$

607

$

639

Japan

94

90

278

318

Principal Markets

207

91

560

248

Strategic Markets

144

145

428

352

Total segment adjusted EBITDA

$

640

$

597

$

1,872

$

1,556

Summary of reconciliation of adjusted EBITDA to consolidated pretax income (loss)

The following table reconciles segment adjusted EBITDA to consolidated pretax income (loss):

Three Months Ended December 31,

Nine Months Ended December 31,

(Dollars in millions)

    

2023

    

2022

    

2023

    

2022

Segment adjusted EBITDA

$

640

$

597

$

1,872

$

1,556

Workforce rebalancing charges

(19)

(10)

(115)

(16)

Charges related to ceasing to use leased/fixed assets and lease terminations

(14)

(10)

(24)

(10)

Transaction-related (costs) benefits

77

(48)

(12)

(218)

Stock-based compensation expense

(25)

(29)

(72)

(81)

Interest expense

(31)

(27)

(92)

(65)

Depreciation of property, equipment and capitalized software

(207)

(232)

(639)

(681)

Amortization expense

(322)

(336)

(968)

(945)

Corporate expense not allocated to the segments

(25)

(16)

(71)

(57)

Other adjustments*

(21)

(27)

(42)

(45)

Pretax income (loss)

$

53

$

(138)

$

(165)

$

(563)

*Other adjustments represent pension expenses other than pension servicing costs and multi-employer plan costs, significant litigation costs, currency impacts of highly inflationary countries, and an adjustment to reduce amortization expense for the amount already included in transaction-related (costs) benefits above.